Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children

Trial Details

NCT ID

NCT06099366

Phase

PHASE2

Sponsor

Hee Young Ju

Status

RECRUITING

Cancer Type

Leukemia

Interventions

• induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal Methotrexate
• Consolidation: Vincristine, Mecaptopurine, Intrathecal Methotrexate
• Consolidation: Vincristine, Mecaptopurine, Cyclophosphamide, Cytarabine, L-asparaginase, Intrathecal Methotrexate
• Interim Maintenance(IM): Vincristine, Methotrexate, Intrathecal Methotrexate
• Interim Maintenance(IM): Vincristine, Methotrexate, Mercaptopurine, Intrathecal Methotrexate
• Delayed Intesification(DI): Vincristine, Mercaptopurine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal Methotrexate

Locations (sample)

• Seoul, Other (Non U.s.), South Korea|37.566,126.9784
• Seoul, Other (Non U.s.), South Korea|37.566,126.9784
• Yangsan, Yangsan-si, South Korea|35.34199,129.03358
• Daegu, South Korea|35.87028,128.59111
• Daejeon, South Korea|36.34913,127.38493

Key Eligibility Criteria

• Newly diagnosed pediatric/adolescent acute lymphomblastic leukemia patient with NCL standard risk that stratifies all 1-4 of following
• 1 year old ≤ Age \< 10 years old
• white blood cell at initial diagnosis \< 5x10\^10/L (50,000uL)
• No testis involvement

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.